DeJong Margaret, Fombonne Eric
South West London and St. George's Mental Health NHS Trust and The Royal Marsden Hospital, Sutton, Surrey, United Kingdom, and McGill University, Montreal, Canada.
J Child Adolesc Psychopharmacol. 2007 Jun;17(3):371-7. doi: 10.1089/cap.2006.0076.
We describe the first four cases of an open-label study investigating the response to citalopram in a depressed pediatric oncology population. Advice from the Committee for Safety of Medicines (CSM) in the United Kingdom warning against the use of serotonin-selective reuptake inhibitor (SSRI) antidepressants other than fluoxetine in this age group led to the discontinuation of the study. Advantages of citalopram over fluoxetine in a medical setting are discussed in terms of its favorable drug-interaction profile and shorter half-life. Citalopram was very well tolerated in these patients and preliminary data are presented that support its efficacy as an antidepressant agent in these patients.
我们描述了一项开放标签研究的前四例病例，该研究旨在调查患有抑郁症的儿科肿瘤患者对西酞普兰的反应。英国药品安全委员会（CSM）发出建议，警告在该年龄组中不要使用除氟西汀以外的5-羟色胺选择性再摄取抑制剂（SSRI）抗抑郁药，导致该研究中断。就西酞普兰在医学环境中相对于氟西汀的优势，讨论了其良好的药物相互作用特性和较短的半衰期。西酞普兰在这些患者中耐受性良好，并提供了初步数据支持其作为这些患者抗抑郁药的疗效。
